TRuE-V Long-Term Extension Study Design
The study design for the TRuE-V long-term extension study is discussed.
In this segment, the discussion between Gary Owens, M.D., and David Rosmarin, M.D., revolves around the design and findings of the TRuE-V long-term extension study for vitiligo. The study segregates patients into two cohorts based on their treatment response. Cohort A consists of highly responsive individuals, randomly assigned either to continue medication or switch to the vehicle arm. Cohort B focuses on patients with less optimal results, exploring the possibility of additional benefits with continued use of ruxolitinib and calcineurin inhibitors. The experts emphasize the study’s significance in addressing questions related to the necessity of indefinite
medication for patients showing a response and the potential for delayed response in those initially less responsive. The discussion highlights the importance of both study arms in understanding vitiligo treatment outcomes and generating valuable insights for the future management of the disease.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
